ArticleCell reports. Medicine2025

Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade.

Lucas Blanchard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.